The risks of hospitalisation for hypoglycaemia (RR 0.69; 95% CI 0.59, 0.82) were reduced with SGLT2 inhibitors and there was no increased risk of UTI hospitalisations (RR 0.52; 95% CI 0.43, 0.63). Here, SLC5A2 is linked to bacterial urinary tract infection.